Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chikushi Anti-Diabetes Mellitus Trial - Lusefi
jRCTs051180060Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luseogliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by Taisho Pharmaceutical. Primary endpoint: Primary: Trend of eGFR over 104 weeks. Started Apr 2018; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs051180060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180060.